Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Patrick DalyAcute Lymphoblastic Leukemia | December 23, 2024
Continued treatment and follow-up of patients after the interim analysis demonstrate the durability of response to revumenib.
Andrew MorenoMeeting News | December 9, 2024
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Melissa BadamoAcute Lymphoblastic Leukemia | November 21, 2024
The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel.
Melissa BadamoAcute Myeloid Leukemia | November 19, 2024
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
Leah LawrencePrint | November 18, 2024
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
Andrew MorenoAcute Lymphoblastic Leukemia | November 13, 2024
The one-year overall survival rate of 90%, and the MRD negativity rate was 94%.
Advertisement
Rebecca AraujoAcute Lymphoblastic Leukemia | September 23, 2024
The phase Ib/II FELIX trial found that obe-cel is effective for the treatment of relapsed or refractory adult B-cell ALL.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | September 10, 2024
In the FELIX trial, obe-cel, a CAR-T therapy, achieved a 78% response rate and a 97% MRD negativity rate.
Melissa BadamoAcute Lymphoblastic Leukemia | September 5, 2024
Researchers identified several risk factors that predicted thrombosis in adults with ALL.
Melissa BadamoAcute Lymphoblastic Leukemia | September 5, 2024
A study described how the implementation of tisa-cel has affected treatment outcomes in B-ALL.
Melissa BadamoAcute Lymphoblastic Leukemia | September 5, 2024
MRD-negative CR status was able to predict long-term survival in newly diagnosed PH+ ALL.
Patrick DalyAcute Lymphoblastic Leukemia | September 16, 2024
Of the 127 patients who received obe-cel infusion, 74% achieved CR/CRi and 95% had MRD negativity.
Patrick DalyAcute Lymphoblastic Leukemia | July 2, 2024
The US FDA approved blinatumomab for the treatment of CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL.
Andrew MorenoAcute Lymphoblastic Leukemia | June 6, 2024
Investigators identified pre- and postinfusion factors linked to severe hematotoxicity, as defined by EHA/EBMT criteria.
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Michel Zwaan, MD, PhDAcute Lymphoblastic Leukemia | April 22, 2024
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
Melissa BadamoAcute Myeloid Leukemia | April 9, 2024
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | September 30, 2024
Efficacy was based on the MRD-negative CR rate at the end of induction.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | July 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | March 6, 2024
The efficacy of inotuzumab ozogamicin was assessed in a multicenter, single-arm, open-label study in 53 pediatric patients.
Advertisement
Advertisement
Editorial Board